Pericytes, inflammation, and diabetic retinopathy

Simple item page
dc.contributor.authorSpencer, B.G.
dc.contributor.authorEstevez, J.J.
dc.contributor.authorLiu, E.
dc.contributor.authorCraig, J.E.
dc.contributor.authorFinnie, J.W.
dc.date.issued2020
dc.description.abstractDiabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.
dc.description.statementofresponsibilityBenjamin G. Spencer, Jose J. Estevez, Ebony Liu, Jamie E. Craig, John W. Finnie
dc.identifier.citationInflammopharmacology, 2020; 28(3):697-709
dc.identifier.doi10.1007/s10787-019-00647-9
dc.identifier.issn0925-4692
dc.identifier.issn1568-5608
dc.identifier.orcidFinnie, J.W. [0000-0003-2277-1693]
dc.identifier.urihttps://hdl.handle.net/2440/146009
dc.language.isoen
dc.publisherSPRINGER BASEL AG
dc.rights© Springer Nature Switzerland AG 2019
dc.source.urihttps://doi.org/10.1007/s10787-019-00647-9
dc.subjectDiabetic retinopathy
dc.subjectInflammation
dc.subjectPericytes
dc.subjectRetina
dc.subject.meshPericytes
dc.subject.meshAnimals
dc.subject.meshHumans
dc.subject.meshDiabetic Retinopathy
dc.subject.meshInflammation
dc.titlePericytes, inflammation, and diabetic retinopathy
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Research Outputs